Volume 3, Issue 4 (Autumn 2022)
J Vessel Circ 2022, 3(4): 165-172 |
Back to browse issues page
Research code: 1583
Ethics code: IR.MUQ.REC.1399.155
Clinical trials code: no
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hejazi S A, Sabokbar T, Aghaali M, Seyyedabadi S M, Paybast S. Investigation of the Risk Factors of COVID-19 Seropositivity and Symptomatic COVID-19 in Patients With Multiple Sclerosis. J Vessel Circ 2022; 3 (4) :165-172
URL: http://jvessels.muq.ac.ir/article-1-252-en.html
URL: http://jvessels.muq.ac.ir/article-1-252-en.html
Seyed Amir Hejazi * 
1, Tayebeh Sabokbar2 , Mohammad Aghaali3 , Seyed Mahdi Seyyedabadi4 , Sepideh Paybast5
1, Tayebeh Sabokbar2 , Mohammad Aghaali3 , Seyed Mahdi Seyyedabadi4 , Sepideh Paybast5
1- Department of Neurology, Neuroscience Research Center, Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran., Qom University of Medical Sciences, Qom, Iran
2- Neuroscience Research Center, Department of Neurology, Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran.
3- Department of Family and Community Medicine, School of Medicine, Qom University of Medical Sciences, Qom, Iran.
4- Department of Neurology, Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran
5- Department of Neurology, School of Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2- Neuroscience Research Center, Department of Neurology, Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran.
3- Department of Family and Community Medicine, School of Medicine, Qom University of Medical Sciences, Qom, Iran.
4- Department of Neurology, Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran
5- Department of Neurology, School of Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract: (474 Views)
Background and Aim: In the current situation of the COVID-19 pandemic, patients with multiple sclerosis (MS) represent a population of particular interest because they may be at higher risk of contracting COVID-19. The present study aims to determine the risk factors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seropositivity and symptomatic COVID-19 in MS patients, in Qom Province, Iran.
Materials and Methods: In this cross-sectional study, 486 patients diagnosed with MS were included in the study. First, the demographic characteristics of patients were collected. Then, the patients underwent serology tests for anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies. Later, the risk factors for SARS-CoV-2 seropositivity and symptomatic COVID-19 were assessed. Finally, SPSS software, version 22 was used to analyze the data.
Results: Fifty-five patients (11.8%) were seropositive for SARS-CoV-2 immunoglobulin G (IgG), of whom 25% were symptomatic. The results showed a significant difference between the seropositive and seronegative groups in terms of MS type and comorbidity. Further, comorbidities, including hypertension and hypothyroidism were identified as the major risk factors for developing symptomatic disease. However, none of the variables were statistically associated with the severity of COVID-19.
Conclusion: The present study revealed a significantly lower seroprevalence of COVID-19 in MS patients than in the population. Based on the results, most seropositive patients were asymptomatic. Comorbidity was identified as the major risk factor for both SARS-CoV-2 seropositivity and symptomatic COVID-19. However, no relationship was observed between patients’ characteristics and MS features with the severity of COVID-19, which reinforces the continuation of regular treatment during the COVID-19 pandemic.
Materials and Methods: In this cross-sectional study, 486 patients diagnosed with MS were included in the study. First, the demographic characteristics of patients were collected. Then, the patients underwent serology tests for anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies. Later, the risk factors for SARS-CoV-2 seropositivity and symptomatic COVID-19 were assessed. Finally, SPSS software, version 22 was used to analyze the data.
Results: Fifty-five patients (11.8%) were seropositive for SARS-CoV-2 immunoglobulin G (IgG), of whom 25% were symptomatic. The results showed a significant difference between the seropositive and seronegative groups in terms of MS type and comorbidity. Further, comorbidities, including hypertension and hypothyroidism were identified as the major risk factors for developing symptomatic disease. However, none of the variables were statistically associated with the severity of COVID-19.
Conclusion: The present study revealed a significantly lower seroprevalence of COVID-19 in MS patients than in the population. Based on the results, most seropositive patients were asymptomatic. Comorbidity was identified as the major risk factor for both SARS-CoV-2 seropositivity and symptomatic COVID-19. However, no relationship was observed between patients’ characteristics and MS features with the severity of COVID-19, which reinforces the continuation of regular treatment during the COVID-19 pandemic.
Keywords: Multiple sclerosis, Seroprevalence, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19
Type of Study: Research |
Subject:
vascular neurological diseases
Received: 2023/03/13 | Accepted: 2023/07/17 | Published: 2023/11/1
Received: 2023/03/13 | Accepted: 2023/07/17 | Published: 2023/11/1
References
1. Portaccio E, Fonderico M, Hemmer B, Derfuss T, Stankoff B, Selmaj K, et al. Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. Mult Scler. 2022; 28(1):132-8. [PMID] [DOI:10.1177/13524585211005339]
2. Berger JR, Brandstadter R, Bar-Or A. COVID-19 and MS disease-modifying therapies. Neurol Neuroimmunol Neuroinflamm. 2020; 7(4):e761. [DOI:10.1212/NXI.0000000000000761] [PMID] [PMCID] [DOI:10.1212/NXI.0000000000000761]
3. Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020; 77(9):1079-88. [DOI:10.1001/jamaneurol.2020.2581] [PMID] [PMCID] [DOI:10.1001/jamaneurol.2020.2581]
4. Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. 2020; 43:102195. [DOI:10.1016/j.msard.2020.102195] [PMID] [PMCID] [DOI:10.1016/j.msard.2020.102195]
5. Sormani MP. An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol. 2020; 19(6):481-2. [DOI:10.1016/S1474-4422(20)30147-2] [PMID] [DOI:10.1016/S1474-4422(20)30147-2]
6. Barzegar M, Mirmosayyeb O, Ghajarzadeh M, Nehzat N, Vaheb S, Shaygannejad V, et al. Characteristics of COVID-19 disease in multiple sclerosis patients. Mult Scler Relat Disord. 2020; 45:102276. [DOI:10.1016/j.msard.2020.102276] [PMID] [PMCID] [DOI:10.1016/j.msard.2020.102276]
7. Rostami Mansoor S, Ghasemi-Kasman M. Impact of disease-modifying drugs on the severity of COVID-19 infection in multiple sclerosis patients. J Med Virol. 2021; 93(3):1314-9. [DOI:10.1002/jmv.26593] [PMID] [PMCID] [DOI:10.1002/jmv.26593]
8. Rivas K. What you need to know about coronavirus (COVID-19).
9. Jacofsky D, Jacofsky EM, Jacofsky M. Understanding antibody testing for COVID-19. J Arthroplasty. 2020; 35(7S):S74-81. [DOI:10.1016/j.arth.2020.04.055] [PMID] [PMCID] [DOI:10.1016/j.arth.2020.04.055]
10. Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: A population-based cross-sectional study. Lancet Infect Dis. 2021; 21(4):473-81. [PMID] [DOI:10.1016/S1473-3099(20)30858-6]
11. Capasso N, Palladino R, Montella E, Pennino F, Lanzillo R, Carotenuto A, et al. Prevalence of SARS-CoV-2 antibodies in multiple sclerosis: The hidden part of the iceberg. J Clin Med. 2020; 9(12):4066. [DOI:10.3390/jcm9124066] [PMID] [PMCID] [DOI:10.3390/jcm9124066]
12. Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, et al. 'Multiple Sclerosis Therapy Consensus Group' (MSTCG). Multiple Sclerosis Therapy Consensus Group (MSTCG): Position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord. 2021; 14:17562864211039648. [DOI:10.1177/17562864211039648] [PMID] [PMCID] [DOI:10.1177/17562864211039648]
13. Barzegar M, Mirmosayyeb O, Gajarzadeh M, Afshari-Safavi A, Nehzat N, Vaheb S, et al. COVID-19 among patients with multiple sclerosis: A systematic review. Neurol Neuroimmunol Neuroinflamm. 2021; 8(4):e1001. [DOI:10.1212/NXI.0000000000001001] [PMID] [PMCID] [DOI:10.1212/NXI.0000000000001001]
14. Cabreira V, Abreu P, Soares-Dos-Reis R, Guimarães J, Sá MJ. Multiple sclerosis, disease-modifying therapies and COVID-19: A systematic review on immune response and vaccination recommendations. Vaccines (Basel). 2021; 9(7):773. [DOI:10.3390/vaccines9070773] [PMID] [PMCID] [DOI:10.3390/vaccines9070773]
15. Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020; 77(2):184-91. [DOI:10.1001/jamaneurol.2019.3365] [PMID] [PMCID] [DOI:10.1001/jamaneurol.2019.3365]
16. Palermo E, Di Carlo D, Sgarbanti M, Hiscott J. Type I interferons in COVID-19 pathogenesis. Biol (Basel). 2021; 10(9):829. [DOI:10.3390/biology10090829] [PMID] [PMCID] [DOI:10.3390/biology10090829]
17. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015; 15(2):87-103. [DOI:10.1038/nri3787] [PMID] [PMCID] [DOI:10.1038/nri3787]
18. Sahraian MA, Azimi A, Navardi S, Ala S, Naser Moghadasi A. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord. 2020; 46:102472. [DOI:10.1016/j.msard.2020.102472] [PMID] [PMCID] [DOI:10.1016/j.msard.2020.102472]
19. Fan M, Qiu W, Bu B, Xu Y, Yang H, Huang D, et al. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2020; 7(5):e787. [DOI:10.1212/NXI.0000000000000787] [PMID] [PMCID] [DOI:10.1212/NXI.0000000000000787]
20. Loonstra FC, Hoitsma E, van Kempen ZL, Killestein J, Mostert JP. COVID-19 in multiple sclerosis: The Dutch experience. Mult Scler. 2020; 26(10):1256-60. [DOI:10.1177/1352458520942198] [PMID] [PMCID] [DOI:10.1177/1352458520942198]
21. Parrotta E, Kister I, Charvet L, Sammarco C, Saha V, Charlson RE, et al. COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center. Neurol Neuroimmunol Neuroinflamm. 2020; 7(5):e835. [DOI:10.1212/NXI.0000000000000835] [PMID] [PMCID] [DOI:10.1212/NXI.0000000000000835]
22. Möhn N, Konen FF, Pul R, Kleinschnitz C, Prüss H, Witte T, et al. Experience in multiple sclerosis patients with COVID-19 and disease-modifying therapies: A review of 873 published cases. J Clin Med. 2020; 9(12):4067. [DOI:10.3390/jcm9124067] [PMID] [PMCID] [DOI:10.3390/jcm9124067]
23. Diaz de la Fe A, Peláez Suárez AA, Fuentes Campos M, Cabrera Hernández MN, Goncalves CA, Schultz S, et al. SARS-CoV-2 infection and risk management in multiple sclerosis. Diseases. 2021; 9(2):32. [DOI:10.3390/diseases9020032] [PMID] [PMCID] [DOI:10.3390/diseases9020032]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Owned by Qom University of Medical Sciences
Published by Qom University of Medical Sciences Press
eISSN: 2717-0357
Email: jvessels[at]muq.ac.ir
j.vessels.circul[at]gmail.com
